

Surrey & North West Sussex Area Prescribing Committee

<b>Policy Statement</b>	Febuxostat for the management of chronic hyperuricaemia in gout (NICE TA 164)
<b>Policy No:</b>	PCN 361 - 2018 (replaces PCN 58-2013)
<b>Date of Issue</b>	September 2018
<b>Review Date:</b>	<p><i>No review date will be assigned to any drugs or devices that are subject to a NICE Technology appraisal.</i></p> <p><i>The recommendation made by the APC (formerly PCN) will be reviewed when new published evidence becomes available OR there is new published national guidance e.g. NICE)</i></p>
<p><b>Recommendations:</b>            The Prescribing Clinical Network recommends the use of febuxostat in line with NICE TA 164, for the management of chronic hyperuricaemia in gout only for people who are intolerant of allopurinol (as defined in TA) or for whom allopurinol is contraindicated.</p> <p>Febuxostat is considered to have a GREEN status on the traffic light system.</p>	
<p><b>Key Considerations:</b></p> <ul style="list-style-type: none"> <li>For the purposes of this guidance, intolerance of allopurinol is defined as adverse effects that are sufficiently severe to warrant its discontinuation, or to prevent full dose escalation for optimal effectiveness as appropriate within its marketing authorisation.</li> <li>This is a review of the PCN recommendation made in May 2013</li> </ul>	
<b>Date taken to Area Prescribing Committee</b>	5 <sup>th</sup> September 2018
<b>Agreed by APC members</b>	18 <sup>th</sup> September 2018